

22 July 2024

## Respiri raises \$3 million through Placement

**Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company")**, an eHealth SaaS Company supporting respiratory healthcare management and remote patient monitoring (RPM) in the USA, is pleased to announce that it has received firm commitments to raise \$A3 million (before costs) (the "**Placement**") from sophisticated and professional investors.

The Placement follows recent USA business progress by the Company and further underpins investor confidence in Respiri's strategy, execution capability and leadership.

Under the terms of the Placement, the Company will issue 100,000,000 new fully paid ordinary shares ("**New Shares**") at an issue price of \$0.03 per New Share. This issue price represents a 3.4% premium to the Company's last closing price of \$0.029 on Friday 19 July 2024.

The Placement was organised by the investor pursuant to the Share Subscription Agreement (as summarised in the Company's prospectus dated 18 June 2024 ("**Prospectus**")). The \$3 million raised under the Placement satisfies the remaining commitment to subscribe and pay for Respiri shares under the Share Subscription Agreement, and the Company confirms that such agreement is now concluded.

Separately, the Company is in continued discussions with Principal Wealth Group (a party connected to the investor under the Share Subscription Agreement) for a further A\$5 million share placement which is intended to be completed at an issue price above \$0.03 (3 cents) per Share.

The Placement will utilise the Company's existing placement capacity pursuant to ASX Listing Rules 7.1 and 7.1A capacity. A total of 19,261,000 Shares will be issued in accordance with ASX Listing Rule 7.1 and 80,739,000 Shares will be issued in accordance with ASX Listing Rule 7.1A. The Company expects to complete allotment of the New Shares under the Placement by 9 August 2024.

The Company intends for these monies raised to fund the accelerated execution of the Company's US commercialisation strategy including patient recruitment and onboarding, its differentiating Clinic in Cloud (CiC) services and finalising the risk share capitated contracts currently underway. These are all critical to achieving the Company's goal of breaking even in cashflow by late 2024.

Respiri is pleased with the strong market support and endorsement of the strategic opportunities as the Company continues to pursue the large Remote Patient Monitoring market in the USA.

-ENDS-

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.*

---

### About Respiri Limited – A Revolutionary Remote Healthcare Solutions Provider

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is leading the charge in transforming healthcare delivery in the US. As an innovator in medical devices and MedTech, we combine state-of-the-art technologies with unparalleled clinical expertise. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

Respiri Limited | ABN 98 009 234 173 | Suite 1, Level 9, 432 St Kilda Road, MELBOURNE VIC 3004



We're revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at [www.respiri.co/au](http://www.respiri.co/au)

#### About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us> or for [wheezo®](#)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiri Limited

#### Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.